KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Operations (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Cash from Operations for 16 consecutive years, with 19370549.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 1.49% to 19370549.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 88629430.0 through Dec 2025, up 14.84% year-over-year, with the annual reading at 88629430.0 for FY2025, 14.84% up from the prior year.
  • Cash from Operations hit 19370549.0 in Q4 2025 for Inovio Pharmaceuticals, up from 21573495.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 19370549.0 in Q4 2025 to a low of 78459231.0 in Q2 2021.
  • Historically, Cash from Operations has averaged 37449774.0 across 5 years, with a median of 30712644.0 in 2023.
  • Biggest five-year swings in Cash from Operations: crashed 188.97% in 2021 and later skyrocketed 56.85% in 2023.
  • Year by year, Cash from Operations stood at 37891163.0 in 2021, then grew by 4.09% to 36340032.0 in 2022, then increased by 27.69% to 26275785.0 in 2023, then increased by 25.16% to 19663909.0 in 2024, then grew by 1.49% to 19370549.0 in 2025.
  • Business Quant data shows Cash from Operations for INO at 19370549.0 in Q4 2025, 21573495.0 in Q3 2025, and 20811359.0 in Q2 2025.